IRINOTECAN (irinotecan HCl)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · METASTATIC COLORECTAL CANCER
ARMAS PHARMACEU
Drug class
Antineoplastic - Topoisomerase I Inhibitors
Antineoplastic topoisomerase I inhibitors are a class of cytotoxic anticancer agents derived primarily from the natural alkaloid camptothecin. Read more about Antineoplastic - Topoisomerase I Inhibitors
31 drugs in this class 25 manufacturers
Drugs in Antineoplastic - Topoisomerase I Inhibitors
ENHERTU (fam-trastuzumab deruxtecan-nxki)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · HER2-POSITIVE CARCINOMA OF BREAST ·+5
DAIICHI SANKYO,
TRODELVY (sacituzumab govitecan-hziy)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · PD-L1 EXPRESSING TRIPLE-NEGATIVE BREAST CANCER ·+2
GILEAD SCIENCES
HYCAMTIN (topotecan HCl)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · SMALL CELL LUNG CARCINOMA ·+3
Novartis Pharmaceuticals
HYCAMTIN (topotecan HCl)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · SMALL CELL LUNG CARCINOMA
Novartis Pharmaceuticals
IRINOTECAN HCL
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · METASTATIC COLORECTAL CANCER
EUGIA US LLC
HYCAMTIN (topotecan HCl)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · SMALL CELL LUNG CARCINOMA
SANDOZ INC.
IRINOTECAN HCL
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · METASTATIC COLORECTAL CANCER
ARMAS PHARMACEU
IRINOTECAN HCL
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · METASTATIC COLORECTAL CANCER
APOTEX/NOVAPLUS
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Topoisomerase I Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic topoisomerase I inhibitors are a class of cytotoxic anticancer agents derived primarily from the natural alkaloid camptothecin.
They exert their therapeutic effect by binding to and stabilizing the transient topoisomerase I–DNA cleavage complex, preventing DNA religation and inducing lethal double-strand DNA breaks during replication, which ultimately triggers tumor cell apoptosis.
Clinically, members of this class—such as irinotecan and topotecan, as well as novel topoisomerase I inhibitor-based antibody-drug conjugates—are predominantly indicated for the management of solid tumors, including advanced colorectal, pancreatic, ovarian, cervical, and small cell lung cancers.
-
fda.gov
Antineoplastic topoisomerase I inhibitors are a class of cytotoxic anticancer agents derived primarily from the natural alkaloid camptothecin
-
nih.gov
Antineoplastic topoisomerase I inhibitors are a class of cytotoxic anticancer agents derived primarily from the natural alkaloid camptothecin Clinically, members of this class—such as irinotecan and topotecan, as well as novel topoisomerase I inhibitor-based antibody-drug conjugates—are predominantly indicated for the management of solid tumors, including advanced colorectal, pancreatic, ovarian, cervical, and small cell lung cancers
-
fda.gov
They exert their therapeutic effect by binding to and stabilizing the transient topoisomerase I–DNA cleavage complex, preventing DNA religation and inducing lethal double-strand DNA breaks during replication, which ultimately triggers tumor cell apoptosis
-
cancer.gov
They exert their therapeutic effect by binding to and stabilizing the transient topoisomerase I–DNA cleavage complex, preventing DNA religation and inducing lethal double-strand DNA breaks during replication, which ultimately triggers tumor cell apoptosis
-
aacrjournals.org
They exert their therapeutic effect by binding to and stabilizing the transient topoisomerase I–DNA cleavage complex, preventing DNA religation and inducing lethal double-strand DNA breaks during replication, which ultimately triggers tumor cell apoptosis
-
fda.gov
Clinically, members of this class—such as irinotecan and topotecan, as well as novel topoisomerase I inhibitor-based antibody-drug conjugates—are predominantly indicated for the management of solid tumors, including advanced colorectal, pancreatic, ovarian, cervical, and small cell lung cancers
-
nih.gov
Clinically, members of this class—such as irinotecan and topotecan, as well as novel topoisomerase I inhibitor-based antibody-drug conjugates—are predominantly indicated for the management of solid tumors, including advanced colorectal, pancreatic, ovarian, cervical, and small cell lung cancers
-
biontech.com
Clinically, members of this class—such as irinotecan and topotecan, as well as novel topoisomerase I inhibitor-based antibody-drug conjugates—are predominantly indicated for the management of solid tumors, including advanced colorectal, pancreatic, ovarian, cervical, and small cell lung cancers
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.